Hepatitis C Therapy - SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders

SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders
National AIDS Treatment Advocacy Project - This was a double-blind, placebo-controlled, 14-day dosing study. The study population was IFN plus or minus ribavirin nonresponders, defined as having had <2 log decline after 12 weeks or more of therapy with interferon. 2005, San Francisco Stefan Zeuzem reported the first study data in patients on this new HCV protease inhibitor of therapy with interferon. Baseline HCV RNA was 30,000 IU/mL

2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+
National AIDS Treatment Advocacy Project - Liver Cancer developed Among Sexual among HCV+ Conference Reports for NATAP AASLD American Association Cancer developed Among Sexual among HCV+ Reported by Jules Levin from AASLD

Long Term Results After Therapy With Pegylated Interferon Alpha 2a (pegasys) In Hcv Positive Liver Transplant
National AIDS Treatment Advocacy Project - of Surgery, Berlin, Ulf P. Neumann, Charite - Campus Virchow, Dep. of Surgery, Berlin, Dietmar Jacob, Charite - Campus Virchow, Dep. of Surgery, 13353 Berlin, Jan M. Langrehr, Charite - Campus Virchow, Dep. INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS Conference Reports INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS Marcus Bahra

Healthbeat:Hepatitis C
WHOI - borne infection caused by the hepatitis C virus (HCV). The virus causes an infection of the liver, which cancer (cirrhosis of the liver). HCV is curable if detected and treated